Cargando…

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells. Idelalisib is a highly selective inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rohrbacher, Lisa, Brauchle, Bettina, Ogrinc Wagner, Ana, von Bergwelt-Baildon, Michael, Bücklein, Veit L., Subklewe, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005712/ https://www.ncbi.nlm.nih.gov/pubmed/33790890 http://dx.doi.org/10.3389/fimmu.2021.608625

Ejemplares similares

Ten things the hematologist wants you to know about CAR-T cells
por: Böll, Boris, et al.
Publicado: (2020)

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
por: Philipp, Nora, et al.
Publicado: (2022)

CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Correction to: CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
por: Cordas dos Santos, David M., et al.
Publicado: (2022)

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells
por: Karschnia, Philipp, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
por: Winkelmann, Michael, et al.
Publicado: (2022)

Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
por: Winkelmann, Michael, et al.
Publicado: (2023)

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
por: Daver, Naval, et al.
Publicado: (2021)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
por: Winkelmann, Michael, et al.
Publicado: (2023)

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report
por: Rejeski, Kai, et al.
Publicado: (2021)

Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
por: Skalt, Daniela, et al.
Publicado: (2022)

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
por: Schoeberl, Florian, et al.
Publicado: (2022)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity
por: Stoecklein, Sophia, et al.
Publicado: (2023)

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
por: Rejeski, Kai, et al.
Publicado: (2023)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
por: Krause, Günter, et al.
Publicado: (2018)

Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients
por: Bücklein, Veit, et al.
Publicado: (2016)

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2012)

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
por: Nixdorf, D., et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
por: Yang, Shida, et al.
Publicado: (2016)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Next-generation dendritic cells for immunotherapy of acute myeloid leukemia
por: Schnorfeil, Frauke, et al.
Publicado: (2014)

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
por: Barrachina, María N., et al.
Publicado: (2021)

Cytokine release syndrome
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2018)

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE
por: Blumenberg, V., et al.
Publicado: (2022)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
por: Adam, Etai, et al.
Publicado: (2017)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat, Yazan F, et al.
Publicado: (2016)

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
por: Maffei, Rossana, et al.
Publicado: (2015)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
por: Köhnke, Thomas, et al.
Publicado: (2022)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5ge92gtpli5fv83qcjs90p2oap